encounter and eventually GC transit. However, the BCL-6 gene was rarely mutated in opposition to normal classical GC B cells and to a substantial proportion of GC-derived lymphomas. One possible hypothesis accounting for the very low BCL-6 mutation rate despite the frequency of the IgV H mutational pattern of NMZL and SMZL could be the absence of GC transit by the tumor cells. It has been shown that normal spleen marginal zone contains a variety of cell types with a functional heterogeneity revealed by their ability to generate both early antibody-forming cells and memory B cells in response to T-dependent and Tindependent antigens. We described previously the existence of different subsets of marginal zone B-cell lymphoma based on their heterogeneous IgV H mutational status. 1 This molecular heterogeneity could eventually simply reflect the diversity of their non-neoplastic B-cell counterparts in marginal zone. However, another hypothesis could be raised taking into account recent advances in the knowledge of B-cell differentiation. The characteristic IgM þ IgD þ CD27 þ peripheral blood B cells, which share phenotypic similarities to marginal zone B cells, have been demonstrated to constitute a B-cell subset distinct from the classical GC-derived memory B cells. 12 Although these B cells hold a mutated immunoglobulin receptor, it was proposed that they undergo a different diversification pathway that does not require a cognate T-B interaction and a GC transit. These B cells appear to be involved in T-independent response. The molecular characteristics of SMZL and NMZL cells lead us to propose that these malignant cells might be derived from this B-cell subset.
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A Traverse-Glehen Myeloproliferative disorders (MPD) such as polycythemia vera (PV), essential thrombocythemia (ET) and chronic idiopathic myelofibrosis (CIMF) are clonal hematopoietic diseases with clinical similarities. By definition, these diseases have been separated from Philadelphia chromosome positive (Ph þ ) chronic myeloid leukemia (CML) requiring negativity for the BCR-ABL transcript in PCR studies of bone marrow or peripheral blood. 1 Although the clonal origin of Ph-negative MPD has been proven, no significant recurring molecular pathology with diagnostic relevance could be described until recently. Several groups independently discovered a gain of function mutation of the Janus kinase 2 (JAK2) gene in Ph-negative MPD. [2] [3] [4] This mutation has been associated with the proliferation of clonogenic progenitors independently of exogenous cytokine stimulation. 2 In addition, recent data point to the fact that the trafficking and constitutive activation of CD34 progenitors can be correlated with the JAK2 mutation status and the relative level of its expression. 5 Most systematic investigations showed that the JAK2 mutation and a BCR-ABL translocation were virtually exclusive and their coexistence was reported in one individual with CML, so far. 6, 7 We report a patient with CIMF in whom a BCR-ABL translocation could be found concurrently with a heterozygous JAK2(V617F) mutation. In vitro investigations suggest that the BCR-ABL translocation occurred as a secondary event restricted to the myeloid lineage but not within the stem cell compartment.
A 66-year-old male patient presented with moderate splenomegaly (3 cm under the costal margin), mild anaemia (11.3 g/dl), elevated lactate dehydrogenase (LDH), an increased count of circulating CD34
þ cells and a dry bone marrow aspirate. According to marrow histology, a MPD, most likely an early stage of CIMF was diagnosed. Six months after initial diagnosis, four Philadelphia chromosome positive metaphases could be detected out of 86 derived from an autologous leukapheresis product harvested and cryopreserved as back-up. BCR-ABL transcripts were found at low levels (BCR-ABL/ABL ratio: 0.2%) in peripheral blood leukocytes by quantitative PCR. Given the differential diagnosis of CML, imatinib mesylate (IM) was started. Owing to haematological toxicities, the dose had to be reduced to 200 mg daily. Although molecular remission for BCR-ABL could be achieved after 18 months, anaemia and splenomegaly persisted. A second bone marrow biopsy performed at that time point, confirmed marrow fibrosis. Imatinib was reinitiated 6 months later, when the quantitative BCR-ABL PCR became positive again. After the PCR method described below had become available, a heterozygous JAK2(V617F) mutation was detected in DNA from the samples drawn by the time of initial diagnosis and in all follow-up samples, including those taken by the time of BCR-ABL-negativity. Despite continuous treatment with IM in the subsequent 12 months, the patient experienced progressive splenomegaly now almost reaching the pelvic boundary, a continuous increase in LDH and progressive anaemia (10 g/dl). Given the results of the available molecular studies, IM was stopped and therapy with hydroxyurea was started.
A cryopreserved sample from the leukapheresis product was thawed and subsequent cell sorting of CD3
þ and CD34 þ cells was performed using a FACS-Vantage cell sorter (www.bd.com). In addition, cells from the leukapheresis product were plated at 1 Â 10 5 ml in Methocult H4531 (www.stemcell.com) according to the manufacturer's instructions. We incubated plates at 371C in a 5% carbon dioxide and 95% air mixture in a humified incubator for 12-14 days. Hematopoietic colonies were assessed and scored using an inverted microscope. Individual colonies were harvested and transferred into cytospin tubes prefilled with 150 ml advanced Dulbecco's modification of Eagle's medium (DMEM) (www.invitrogen.com) for fluorescence-in-situ hybridization (FISH) analysis or mixed with 100 ml of deionized water for DNA isolation.
JAK2(V617F) mutations were detected with ARMS-PCR based on primers reported previously, 8 but the generic primers were labelled with different fluorophores and PCR products were analyzed by Genescan technique. To investigate the level of JAK2 mutations in individual clones, direct sequencing of DNA (sorted populations) or cDNA colony forming units (CFU-E and CFU-GM) was performed (Figure 1a) . BCR-ABL mRNA was quantified by real-time PCR, based on the BCR-ABL/ABL ratio. Chromosome preparation, GTG-banding and FISH were performed according to standard protocols. For metaphase analyses cells were cultured for 2 days. Sorted cells and picked colonies were cytospun before the FISH procedure. 
þ and CD34 þ ) as well as colony forming units (CFU-E and CFU-GM). (a) JAK2 exon 12 was analyzed by PCR and direct sequencing. The antisense sequence was studied to avoid problems with a poly-T stretch in intron 11. JAK2(V617F) was clearly detectable in the myeloid (CD14
JAK2 sequence analysis in CFU-E (upper and middle row, left) and CFU-GM (upper and middle row, right). cDNA was analysed from both populations. The JAK2 mutation could be demonstrated in CFU-E and CFU-GM. Nested-PCR analysis of BCR-ABL mRNA in CFU-E and CFU-GM (middle row, central). BCR-ABL could be found only in CFU-GM, but not in CFU-E. Control gene analysis showed a 10-fold lower cDNA content in CFU-E, but levels were still sufficient to detect BCR-ABL. The BCR-ABL specific fusion signal as detected by fluorescence-in-situ hybridization (FISH) in a representative CFU-GM (bottom row, right). All erythroid colonies (CFU-E) were BCR-ABL-negative (two nuclei, bottom row, left).
At diagnosis, the number of CD34 þ cells in the peripheral blood (65 Â 10 6 l) was in the range described for patients in the fibrotic stage of CIMF or MF after PV. 5 Quantitative PCR revealed a relatively low ratio of BCR-ABL to ABL of 0.2%. Within the leukapheresis product, four out of 86 metaphases were Philadelphia chromosome positive. The percentage of BCR-ABL-positive FISH signals was 14.7%, which is slightly above the cut-off (12.2%). These results already argued for a limited involvement of distinct clonogenic progenitors. Colony assays performed with and without the exogenous addition of erythropoietin revealed no autonomous growth of erythroid colonies suggesting primary myelofibrosis as the most probable diagnosis.
The retrospective PCR analysis confirmed the heterozygous JAK2(V617F) mutation in all marrow and blood samples studied so far. As shown in Figure 1a , the JAK2 mutation could be detected in CD34 þ , CD15 þ and CD14 þ cells, whereas T and B cells were negative. Analysis of pooled CFU-GM and CFU-E revealed the mutation in both progenitor compartments (Figure 1b) . Within pooled colonies, BCR-ABL could only be detected by nested-PCR in CFU-GM but not in CFU-E (Figure 1b) . BCR-ABL FISH was positive in 2 out of 16 CFU-GM, whereas all 15 erythroid colonies were BCR-ABL-negative (Figure 1b) . The two latter findings suggest that the BCR-ABL translocation as a secondary event was limited to a small compartment of myeloid progenitor cells. This hypothesis is supported by FISH -negativity for BCR-ABL within sorted cells derived from the steady-state apheresis.
BCR-ABL transcripts have been detected at very low levels in healthy persons without clinical features of CML, at least 3-4 logs below those measured in this patient. 9 In addition, the BCR-ABL translocation has been found in a limited number of patients with Ph-negative MPD. 10 Therefore, the sole detection of BCR-ABL transcripts in CIMF is not new but we are not aware of a published case with CIMF concurrently presenting with a JAK2 mutation and BCR-ABL translocation. Most current definitions of CIMF require the absence of BCR-ABL transcripts as a diagnostic feature. 1 In general, Ph þ CML is thought to be a stem cell disease. Our results in this case are consistent with the idea that the t (9; 22) in this particular patient occurred at a later stage of myelopoiesis. Owing to this, the BCR-ABL-positive clone had a limited potential for expansion, which might explain that we did not see marked proliferation as in typical CML. A recent report suggests that the progression of CML is mainly associated with an expansion of the CFU-GM compartment harbouring an increased self-renewal capacity.
11 It remains to be speculated why the BCR-ABL translocation had a reduced potential to transform the myeloid progenitor compartment in this case. Since JAK2 has been described as one binding partner of BCR-ABL mediating its transforming effects, the constitutive activation of JAK2 in all common myeloid progenitors might have hampered the clonal expansion of BCR-ABL-positive cells. 12 The limited proportion of BCR-ABLpositive progenitor cells can also be seen as the reason for the failure of IM therapy.
In summary, our clinical and experimental data suggest that the BCR-ABL translocation has a limited transforming capacity in myeloid stem and progenitor cells harbouring the JAK2 mutation. Further studies in larger cohorts with Ph-negative MPD are needed to confirm this initial observation.
